TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acceptability and Feasibility of a Simplified Medical Abortion Regimen in Kazakhstan: A Study of 600 µg Sublingual Misoprostol Following 200 mg Mifepristone for Abortion up to 70 Days Gestation
Brief Summary: The study will be conducted in 4 sites and will examine how a simplified outpatient medical abortion procedure using mifepristone and misoprostol, with the option to take mifepristone at a place of woman's choosing, works in Kazakhstan. The investigators intend to demonstrate the efficacy of oral administration of 200 mg mifepristone and sublingual administration of 600 µg misoprostol with gestations through 70 days, as well as the acceptability of this method. Research questions include:

1. What is the efficacy of regimen of 200 mg mifepristone, followed 24 to 48 hours later by 600 µg sublingual misoprostol and used in gestations of up to 70 days?
2. Is medical abortion procedure consisting of two visits acceptable to women in Kazakhstan?
3. Are the side effects associated with sublingual use of misoprostol acceptable to women?
4. When given a choice, do women prefer to take mifepristone in the clinic or at a place of their choosing?


Options:
A: Arm Label: clinic administration of mifepristone; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: home administration of mifepristone; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): home administration of mifepristone
B: Intervention Type: DRUG; Name: mifepristone and misoprostol; Assigned to Arm(s): N/A
C: Arm Label: In-Center Use of Mifepristone; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Out-of-Center Use of Mifepristone; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): Out-of-Center Use of Mifepristone
D: Arm Label: Women seeking medical abortion; Type: N/A; Interventions: Drug: Mifepristone, misoprostol | Intervention Type: DRUG; Name: Mifepristone, misoprostol; Assigned to Arm(s): Women seeking medical abortion

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Pragmatic Trial About the Effectiveness of an App Based Relaxation Technique for Patients With Chronic Neck Pain
Brief Summary: The aim of the pragmatic randomized study is to evaluate whether additional relaxation technique is more effective in the reduction of chronic neck pain compared to usual care alone.


Options:
A: Arm Label: relaxation; Type: EXPERIMENTAL; Interventions: Behavioral: Relaxation exercise | Arm Label: Usual care waiting list; Type: ACTIVE_COMPARATOR; Interventions: Other: ususal care | Intervention Type: BEHAVIORAL; Name: Relaxation exercise; Assigned to Arm(s): relaxation | Intervention Type: OTHER; Name: ususal care; Assigned to Arm(s): Usual care waiting list
B: Arm Label: usual care waiting list; Type: ACTIVE_COMPARATOR; Interventions: Other: ususal care | Arm Label: relaxation exercise; Type: EXPERIMENTAL; Interventions: Behavioral: relaxation exercise | Intervention Type: BEHAVIORAL; Name: relaxation exercise; Assigned to Arm(s): relaxation exercise | Intervention Type: OTHER; Name: ususal care; Assigned to Arm(s): usual care waiting list
C: Arm Label: DAHLIA treatment; Type: EXPERIMENTAL; Interventions: Behavioral: DAHLIA treatment | Arm Label: Treatment as usual; Type: OTHER; Interventions: Other: Treatment as usual | Intervention Type: BEHAVIORAL; Name: DAHLIA treatment; Assigned to Arm(s): DAHLIA treatment | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): Treatment as usual
D: Arm Label: Distraction-Based VR; Type: ACTIVE_COMPARATOR; Interventions: Device: Distraction-Based VR, Device: Activity Tracker | Arm Label: Sham VR; Type: SHAM_COMPARATOR; Interventions: Device: Sham VR, Device: Activity Tracker | Arm Label: Skills-Based VR; Type: EXPERIMENTAL; Interventions: Device: Skills-Based VR, Device: Activity Tracker | Intervention Type: DEVICE; Name: Distraction-Based VR; Assigned to Arm(s): Distraction-Based VR | Intervention Type: DEVICE; Name: Sham VR; Assigned to Arm(s): Sham VR | Intervention Type: DEVICE; Name: Skills-Based VR; Assigned to Arm(s): Skills-Based VR | Intervention Type: DEVICE; Name: Activity Tracker; Assigned to Arm(s): Distraction-Based VR, Sham VR, Skills-Based VR

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk factors.


Options:
A: Arm Label: Sibutramine; Type: EXPERIMENTAL; Interventions: Drug: Sibutramine hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Lead-in sibutramine; Type: EXPERIMENTAL; Interventions: Drug: Sibutramine hydrochloride | Intervention Type: DRUG; Name: Sibutramine hydrochloride; Assigned to Arm(s): Sibutramine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sibutramine hydrochloride; Assigned to Arm(s): Lead-in sibutramine
B: Intervention Type: DRUG; Name: Rimonabant (SR141716); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
C: Arm Label: Lorcaserin hydrochloride (HCL)10 mg; Type: EXPERIMENTAL; Interventions: Drug: Lorcaserin hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lorcaserin hydrochloride; Assigned to Arm(s): Lorcaserin hydrochloride (HCL)10 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Rimonabant; Type: EXPERIMENTAL; Interventions: Drug: Rimonabant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Rimonabant) | Intervention Type: DRUG; Name: Rimonabant; Assigned to Arm(s): Rimonabant | Intervention Type: DRUG; Name: Placebo (for Rimonabant); Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Pragmatic Trial About the Effectiveness of an App Based Relaxation Technique for Patients With Chronic Low Back Pain
Brief Summary: The aim of the pragmatic randomized study is to evaluate whether additional relaxation technique is more effective in the reduction of chronic low back pain compared to usual care alone.


Options:
A: Intervention Type: BEHAVIORAL; Name: self-management program; Assigned to Arm(s): N/A
B: Arm Label: relaxation; Type: EXPERIMENTAL; Interventions: Behavioral: Relaxation exercise | Arm Label: Usual care waiting list; Type: ACTIVE_COMPARATOR; Interventions: Other: ususal care | Intervention Type: BEHAVIORAL; Name: Relaxation exercise; Assigned to Arm(s): relaxation | Intervention Type: OTHER; Name: ususal care; Assigned to Arm(s): Usual care waiting list
C: Arm Label: Distraction-Based VR; Type: ACTIVE_COMPARATOR; Interventions: Device: Distraction-Based VR, Device: Activity Tracker | Arm Label: Sham VR; Type: SHAM_COMPARATOR; Interventions: Device: Sham VR, Device: Activity Tracker | Arm Label: Skills-Based VR; Type: EXPERIMENTAL; Interventions: Device: Skills-Based VR, Device: Activity Tracker | Intervention Type: DEVICE; Name: Distraction-Based VR; Assigned to Arm(s): Distraction-Based VR | Intervention Type: DEVICE; Name: Sham VR; Assigned to Arm(s): Sham VR | Intervention Type: DEVICE; Name: Skills-Based VR; Assigned to Arm(s): Skills-Based VR | Intervention Type: DEVICE; Name: Activity Tracker; Assigned to Arm(s): Distraction-Based VR, Sham VR, Skills-Based VR
D: Arm Label: usual care waiting list; Type: ACTIVE_COMPARATOR; Interventions: Other: ususal care | Arm Label: relaxation exercise; Type: EXPERIMENTAL; Interventions: Behavioral: relaxation exercise | Intervention Type: BEHAVIORAL; Name: relaxation exercise; Assigned to Arm(s): relaxation exercise | Intervention Type: OTHER; Name: ususal care; Assigned to Arm(s): usual care waiting list

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Postmarketing Study to Evaluate the Placental Transfer of Certolizumab Pegol in Pregnant Women Receiving Treatment With Cimzia® (Certolizumab Pegol)
Brief Summary: The primary purpose is to assess whether there is transfer of Certolizumab Pegol (CZP) from pregnant women receiving treatment with Cimzia® across the placenta to infants by evaluating the concentration of CZP in the plasma of infants at birth.


Options:
A: Arm Label: Pharmacokinetic samples; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling from mother, Procedure: Blood sampling from infant, Procedure: Blood sampling from umbilical cord, Biological: Certolizumab Pegol | Intervention Type: PROCEDURE; Name: Blood sampling from mother; Assigned to Arm(s): Pharmacokinetic samples | Intervention Type: PROCEDURE; Name: Blood sampling from infant; Assigned to Arm(s): Pharmacokinetic samples | Intervention Type: PROCEDURE; Name: Blood sampling from umbilical cord; Assigned to Arm(s): Pharmacokinetic samples | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol; Assigned to Arm(s): Pharmacokinetic samples
B: Arm Label: CDP870 400 mg; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): CDP870 400 mg
C: Arm Label: Certolizumab Pegol; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol (CDP870) | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): Certolizumab Pegol
D: Arm Label: Certolizumab pegol; Type: EXPERIMENTAL; Interventions: Biological: certolizumab pegol (CDP870, CZP) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: certolizumab pegol (CDP870, CZP); Assigned to Arm(s): Certolizumab pegol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis
Brief Summary: Purpose: To determine whether oral viscous budesonide (OVB) or fluticasone metered dose inhaler (MDI) most effectively treats EoE by improving histologic findings and symptoms, which medication provides a more durable treatment response, and whether biomarkers can predict treatment response.

Participants: A total of up to 200 16-80 year old patients with a new diagnosis of eosinophilic esophagitis (EoE) who are referred for upper endoscopy will be consented with a target of 122 randomized.

Procedures: This will be a prospective, randomized, double-blind, double-dummy, clinical trial comparing OVB to fluticasone MDI for treatment of EoE. This overall study design will generate data for all three Aims


Options:
A: Arm Label: RPC4046 Low Dose; Type: EXPERIMENTAL; Interventions: Drug: RPC4046 | Arm Label: RPC4046 High Dose; Type: EXPERIMENTAL; Interventions: Drug: RPC4046 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: RPC4046; Assigned to Arm(s): RPC4046 High Dose, RPC4046 Low Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Low dose budesonide tablet; Type: EXPERIMENTAL; Interventions: Drug: low dose budesonide tablet | Arm Label: High dose budesonide tablet; Type: EXPERIMENTAL; Interventions: Drug: high dose budesonide tablet | Arm Label: High dose budesonide suspension; Type: EXPERIMENTAL; Interventions: Drug: high dose budesonide suspension | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: low dose budesonide tablet; Assigned to Arm(s): Low dose budesonide tablet | Intervention Type: DRUG; Name: high dose budesonide tablet; Assigned to Arm(s): High dose budesonide tablet | Intervention Type: DRUG; Name: high dose budesonide suspension; Assigned to Arm(s): High dose budesonide suspension | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Oral Viscous Budesonide (OVB); Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral Viscous Budesonide, Drug: Placebo inhaler | Arm Label: Active Fluticasone MDI; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone MDI, Drug: Placebo slurry | Intervention Type: DRUG; Name: Oral Viscous Budesonide; Assigned to Arm(s): Oral Viscous Budesonide (OVB) | Intervention Type: DRUG; Name: Fluticasone MDI; Assigned to Arm(s): Active Fluticasone MDI | Intervention Type: DRUG; Name: Placebo slurry; Assigned to Arm(s): Active Fluticasone MDI | Intervention Type: DRUG; Name: Placebo inhaler; Assigned to Arm(s): Oral Viscous Budesonide (OVB)
D: Arm Label: Mometasone furoat; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate | Arm Label: Placebo spray; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mometasone furoate; Assigned to Arm(s): Mometasone furoat | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo spray

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Aerobic Training in Patients With Congenital Myopathies
Brief Summary: Congenital myopathies are clinical and genetic heterogeneous disorders characterized by skeletal muscle weakness. Most patients experience muscle weakness and fatigue throughout their life. However, progression of symptoms is rare. There are no specific treatments for congenital myopathies. Training has been shown to benefit several other muscle diseases with weakness, but the defect in congenital myopathies involves contractile proteins of the sarcomere, why the effect of training is uncertain in these conditions. The investigators will therefore investigate the effect cycle-ergometer training for 30 minutes, three times weakly, for ten weeks in 15 patients with congenital myopathy. Another 5-10 congenital myopathy patients, who do not train, will serve as controls for the trained patients. The study starts and ends with a test day, where efficacy based on VO2max, performance in functional tests and a questionnaire will be assessed.


Options:
A: Arm Label: Sjogren and Myositis Control (no control for takayasu's); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Sjogren, Myositis and Takayasu's Trained; Type: EXPERIMENTAL; Interventions: Other: Exercise training | Intervention Type: OTHER; Name: Exercise training; Assigned to Arm(s): Sjogren, Myositis and Takayasu's Trained
B: Arm Label: Behavioural change intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioural change intervention | Arm Label: Standard Patient Management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioural change intervention; Assigned to Arm(s): Behavioural change intervention
C: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Exercise on a cycle-ergometer | Arm Label: Controls; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise on a cycle-ergometer; Assigned to Arm(s): Exercise
D: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Physical Exercise | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Physical Exercise; Assigned to Arm(s): Exercise

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Pain during intrauterine device (IUD) insertion can be a barrier to initiation. Misoprostol and nonsteroidal drugs have found to be ineffective by clinical trials.Investigators tested whether intracervical 2% lidocaine gel decreased insertion pain compared to placebo.


Options:
A: Arm Label: saline spray application; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: lidocaine spray application; Type: EXPERIMENTAL; Interventions: Drug: Lidocaine Spray | Intervention Type: DRUG; Name: Lidocaine Spray; Assigned to Arm(s): lidocaine spray application | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): saline spray application
B: Arm Label: misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo gel | Arm Label: Study Group; Type: EXPERIMENTAL; Interventions: Drug: 2% lidocaine gel | Intervention Type: DRUG; Name: 2% lidocaine gel; Assigned to Arm(s): Study Group | Intervention Type: DRUG; Name: Placebo gel; Assigned to Arm(s): Control Group
D: Arm Label: lidocaine gel; Type: EXPERIMENTAL; Interventions: Drug: 2% lidocaine gel | Arm Label: placebo gel (surgilube); Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: 2% lidocaine gel; Assigned to Arm(s): lidocaine gel | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo gel (surgilube)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel-group, 24-week Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension
Brief Summary: Study to evaluate if macitentan is efficient, safe and tolerable enough to be used for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH).


Options:
A: Arm Label: Ambrisentan; Type: EXPERIMENTAL; Interventions: Drug: Ambrisentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ambrisentan; Assigned to Arm(s): Ambrisentan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Combination therapy; Type: EXPERIMENTAL; Interventions: Drug: Iloprost, Drug: Bosentan | Arm Label: monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bosentan | Intervention Type: DRUG; Name: Iloprost; Assigned to Arm(s): Combination therapy | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Combination therapy, monotherapy
C: Arm Label: Macitentan; Type: EXPERIMENTAL; Interventions: Drug: Macitentan 10 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Macitentan 10 mg; Assigned to Arm(s): Macitentan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Macitentan; Type: EXPERIMENTAL; Interventions: Drug: Macitentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Macitentan; Assigned to Arm(s): Macitentan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis
Brief Summary: The primary objective of this study was to evaluate the efficacy of roxadustat compared to darbepoetin alfa in the treatment of anemia in nondialysis-dependent chronic kidney disease (NDD CKD) participants.


Options:
A: Arm Label: Vadadustat; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Vadadustat; Assigned to Arm(s): Vadadustat | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
B: Arm Label: ASP1517 low dose group; Type: EXPERIMENTAL; Interventions: Drug: ASP1517 | Arm Label: ASP1517 middle dose group; Type: EXPERIMENTAL; Interventions: Drug: ASP1517 | Arm Label: ASP1517 high dose group; Type: EXPERIMENTAL; Interventions: Drug: ASP1517 | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ASP1517; Assigned to Arm(s): ASP1517 high dose group, ASP1517 low dose group, ASP1517 middle dose group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo group
C: Arm Label: ASP1517 Low dose Group; Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Arm Label: ASP1517 High dose Group; Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Intervention Type: DRUG; Name: roxadustat; Assigned to Arm(s): ASP1517 High dose Group, ASP1517 Low dose Group
D: Arm Label: Roxadustat; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Roxadustat; Assigned to Arm(s): Roxadustat | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Omega-3 for Depression and Other Cardiac Risk Factors-2
Brief Summary: The purpose of this 10 week randomized, placebo-controlled, double-blind clinical trial is to determine whether antidepressant augmentation with two grams of EPA omega-3 per day is superior to antidepressant therapy alone for major depression in patients with coronary heart disease (CHD).


Options:
A: Arm Label: Omega-3 supplement; Type: EXPERIMENTAL; Interventions: Drug: Omega-3 supplement | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omega-3 supplement; Assigned to Arm(s): Omega-3 supplement | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: EPA 3.5 g/day; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Omega-3 fatty acids | Arm Label: Placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Omega-3 fatty acids | Arm Label: DHA 1.75 g/day; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega-3 fatty acids | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 fatty acids; Assigned to Arm(s): DHA 1.75 g/day, EPA 3.5 g/day, Placebo capsules
C: Arm Label: Fish oil concentrate; Type: EXPERIMENTAL; Interventions: Drug: Fish oil concentrate | Arm Label: Placebo oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fish oil concentrate; Assigned to Arm(s): Fish oil concentrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo oil
D: Arm Label: 2:1 EPA/DHA; Type: ACTIVE_COMPARATOR; Interventions: Drug: 2:1 EPA/DHA | Arm Label: High EPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: High EPA | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: 2:1 EPA/DHA; Assigned to Arm(s): 2:1 EPA/DHA | Intervention Type: DRUG; Name: High EPA; Assigned to Arm(s): High EPA | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A